Bispecific Antibodies in Multiple Myeloma

Pooled Analysis on Bispecific Antibody-Related Toxicities in Multiple ...

Background: Multiple myeloma (MM) is a hematologic malignancy caused by the uncontrolled proliferation of malignant plasma cells in the bone marrow. Bispecific ...

A Real-World Study of Bispecific Antibodies in Multiple Myeloma

Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are ...

Optimizing Bispecific Antibody Therapy in Multiple Myeloma

This resource guide is a review of bispecific antibodies, one of the new therapies currently being studied in clinical trials for patients with RRMM.

“Impressive” Efficacy in Trial Combining Bispecific Antibodies for ...

Results of a phase 1b study evaluating the combination of two bispecific antibodies in patients with relapsed or refractory multiple myeloma ...

Bispecific antibodies: New hope in multiple myeloma - BJH

Bispecific antibodies simultaneously target tumour cells and patient's own effector immune cells, activating the latter close to the former leading to the ...

Bispecific antibodies in multiple myeloma: their current role and the ...

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, ...

More on Multiple Myeloma From ASCO 2023 Focus on Bispecific ...

Two new bispecific antibodies—teclistamab and talquetamab—have been shown to be active in relapsed or refractory multiple myeloma when used in ...

Bispecific Antibody Combos for R/R Myeloma: What to Know

Tara Gregory, MD, explains what bispecific antibody combinations have been approved for relapsed/refractory multiple myeloma, potential side ...

Bispecifics Part 3: The Pros and Cons of Bispecifics

Because bispecifics attached to both the myeloma cell and a local immune cell, that immune cell can be activated to kill the myeloma. There is a ...

How to best sequence bispecific antibodies and CAR-T therapy in ...

ASCO 2023 | How to best sequence bispecific antibodies and CAR-T therapy in multiple myeloma ... Surbhi Sidana, MD, Stanford University, Stanford, ...

What are the pros and cons of bispecific antibodies for multiple ...

During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J.

Teclistamab in Relapsed or Refractory Multiple Myeloma

Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on ...

Immunodeficiency With Bispecific Antibody Therapy in Relapsed ...

Bispecific antibodies (bsAb) targeting novel antigens are a promising class of therapeutics for relapsed refractory multiple myeloma (RRMM).

Prevention and Management of Bispecific Antibody Associated ...

This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has ...

What Are Bispecific Antibodies? - Patient Power

An expert explains what bispecific antibody combinations have been approved for relapsed/refractory multiple myeloma and potential side effects.

Multiple Myeloma Resource Center - JADPRO

Test your knowledge of relapsed multiple myeloma and bispecific antibodies · Teclistamab is a bispecific antibody directed against CD3 and which ...

Dual-targeting bispecific antibody alnuctamab in R/R multiple ...

The bispecific antibody alnuctamab elicits an immune response through dual targeting of B-cells via the B-cell maturation antigen (BCMA) and T- ...

The role of bispecific antibodies in the treatment of ... - YouTube

... bispecific antibodies in the treatment of multiple myeloma (MM). In the past few years, three bispecifics have been approved for MM. They ...

Using the available repertoire of bispecific antibodies for treating ...

In this video, Paola Neri, MD, PhD, University of Calgary, Calgary, Canada, outlines the bispecific antibodies available for treating multiple myeloma (MM)

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for ...

Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.